Jefferies Global Healthcare Conference
Logotype for Rapport Therapeutics Inc

Rapport Therapeutics (RAPP) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Rapport Therapeutics Inc

Jefferies Global Healthcare Conference summary

16 Nov, 2026

Pipeline and strategic positioning

  • RAP-219 achieved proof of concept in focal onset seizures in 2025 and bipolar mania in 2026; ~$814M in cash is expected to fund development through 2029.

  • FOCUS 1 and FOCUS 2 Phase III trials are enrolling; a Phase III program in primary generalized tonic-clonic seizures is planned for H1 2027.

  • RAP-219 bipolar mania Phase III is planned for H2 2027, following a Q1 2027 FDA End-of-Phase II meeting; two parallel studies are planned.

  • RAP-641, an α6β4 nicotinic program for migraine and neuropathic pain, is targeted to enter Phase I in 2027, with results expected in H2 2027.

Focal onset seizures

  • Phase II enrolled refractory focal onset seizure patients with RNS devices, enabling continuous EEG assessment alongside clinical seizure tracking.

  • RAP-219 reduced electrographic seizures by ~71% and clinical seizures by 78%; 24% of patients achieved seizure freedom.

  • Treatment was well tolerated; the most common adverse events were mild to moderate dizziness, headache and fatigue.

  • Phase III studies are powered conservatively, consistent with recent programs targeting a 30%–35% placebo-adjusted reduction in seizure frequency.

Bipolar mania

  • In a 21-day, placebo-controlled Phase II trial of 253 patients, RAP-219 showed a 3.1-point placebo-adjusted YMRS difference at week 3 and a 15.4-point absolute change in the treatment arm.

  • All 11 YMRS items improved; four were statistically significant. The secondary CGI scale showed a significant 0.4-point treatment difference versus placebo.

  • Adverse events were mild to moderate; AE-related withdrawal was 3.2% with RAP-219 versus 0.8% with placebo, while overall treatment discontinuations were not driven by AEs.

  • Phase III design may use 1.25 mg versus 0.75 mg in Phase II to achieve higher receptor occupancy earlier; global sites are under consideration to manage placebo response.

  • Phase III planning discussed three studies to secure at least two positive results; the design discussion cited 90% power, α=0.05 and a YMRS difference in the four-point range.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Rapport Therapeutics